Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0

Nonlinear mixed effect models (NLMEM) with multiple responses are increasingly used in pharmacometrics, one of the main examples being the joint analysis of the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug. Efficient tools for design evaluation and optimisation in NLMEM are necessary. The R functions PFIM 1.2 and PFIMOPT 1.0 were proposed for these purposes, but accommodate only single response models. The methodology used is based on the Fisher information matrix, developed using a linearisation of the model. In this paper, we present an extended version, PFIM 3.0, dedicated to both design evaluation and optimisation for multiple response models, using a similar method as for single response models. In addition to handling multiple response models, several features have been integrated into PFIM 3.0 for model specification and optimisation. The extension includes a library of classical analytical pharmacokinetics models and allows the user to describe more complex models using differential equations. Regarding the optimisation algorithm, an alternative to the Simplex algorithm has been implemented, the Fedorov-Wynn algorithm to optimise more practical D-optimal design. Indeed, this algorithm optimises design among a set of sampling times specified by the user. This R function is freely available at http://www.pfim.biostat.fr. The efficiency of this approach and the simplicity of use of PFIM 3.0 are illustrated with a real example of the joint PKPD analysis of warfarin, an oral anticoagulant, with a model defined by ordinary differential equations.

[1]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[3]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[4]  N. Holford Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.

[5]  L. Petzold Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations , 1983 .

[6]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[7]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[9]  W. Näther Optimum experimental designs , 1994 .

[10]  P M Aggeler,et al.  Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.

[11]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[12]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Jon Wakefield,et al.  Population modelling in drug development , 1999, Statistical methods in medical research.

[14]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[15]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[16]  N H Holford,et al.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. , 1986, Clinical pharmacokinetics.

[17]  France Mentré,et al.  Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Andrew C. Hooker,et al.  Software for optimal design in population pharmacokinetics and pharmacodynamics : a comparison , 2007 .

[19]  France Mentré,et al.  Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.

[20]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[21]  Leon Aarons,et al.  Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.

[22]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[23]  France Mentré,et al.  Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model , 2009, Statistics in medicine.

[24]  Malcolm Rowland,et al.  Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[26]  Paolo Vicini,et al.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.

[27]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[28]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[29]  France Mentré,et al.  Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics , 2009 .

[30]  R. S. Stepleman,et al.  Scientific computing : applications of mathematics and computing to the physical sciences , 1983 .